ANN ARBOR, Mich.--(BUSINESS WIRE)--BlueWillow Biologics, Inc. today announced that the company will present positive interim data from its phase 1 clinical trial of a novel intranasal anthrax vaccine at a Lightning Talks Session of BARDA’s Industry Day, November 3 and 4, 2021.
BlueWillow’s rPA/NE01 anthrax vaccine, BW-1010, developed in collaboration with Porton Biopharma Limited (UK) and funded by the National Institute of Allergy and Infectious Diseases, is an intranasal recombinant protein vaccine candidate against anthrax with proven safety and immunogenicity data in humans that can potentially protect from infection, disease and carriage. BlueWillow has received funding support as a subaward under NIAID contract HHSN272201600045C to PBL. The phase 1 trial was completed in September 2021, setting the stage for advancement to late-stage clinical development as early as 2023.
About BlueWillow Biologics
BlueWillow Biologics is developing a new generation of safe and effective nasal vaccines to help protect humankind from respiratory infections, sexually transmitted diseases and food allergies. Our novel intranasal antigen delivery technology platform activates mucosal immunity, the body’s first line of defense, while also inducing systemic immunity. We are a clinical-stage company advancing a pipeline of proprietary programs including COVID-19, pandemic flu, RSV, HSV, anthrax and peanut allergy (www.bluewillow.com).
PBL is a biopharmaceutical development and manufacturing company with approximately 400 staff. It was formed in April 2015 as a spin-out company of Public Health England, and has a sole shareholder in the Department of Health and Social Care. PBL is based at Porton Down, Wiltshire, which has a long history of pharmaceutical development and manufacturing.